Loading…
Loading…
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company's stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,586 shares of the company's stock, valued at approximately $9,551,000. Deutsche Bank AG owned 0.13% of Mirum Pharmaceuticals at the end
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.